Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study (PEARL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04488601
Recruitment Status : Recruiting
First Posted : July 28, 2020
Last Update Posted : October 5, 2021
Sponsor:
Collaborator:
University of California, Los Angeles
Information provided by (Responsible Party):
AgelessRx

Brief Summary:
This is a randomized, placebo-controlled trial into the safety and efficacy in reducing clinical measures of aging in an older adult population.

Condition or disease Intervention/treatment Phase
Aging Drug: Rapamycin Drug: Placebo Phase 2

Detailed Description:
A randomized, double-blind, placebo-controlled trial assessing the effects of low and high doses of intermittent Rapamycin on a weekly schedule. The researchers aim to establish a long-term safety profile, determine the long-term efficacy of Rapamycin in reducing clinical aging measures, and biochemical and physiological endpoints associated with declining health and aging in healthy older adults.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Prospective, Double-Blind, Placebo-Controlled Trial
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study (PEARL): A Prospective, Double-Blind, Placebo-Controlled Trial for Rapamycin in Healthy Individuals Assessing Safety and Efficacy in Reducing Aging Effects
Actual Study Start Date : January 1, 2020
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Rapamycin 5
Rapamycin 5 mg/week
Drug: Rapamycin
Rapamycin in 2 different dosage forms.
Other Names:
  • Sirolimus
  • Rapamune
  • Rapacan
  • Siromus
  • Raparen
  • Rapasim
  • Sirova

Experimental: Rapamycin 10
Rapamycin 10 mg/week
Drug: Rapamycin
Rapamycin in 2 different dosage forms.
Other Names:
  • Sirolimus
  • Rapamune
  • Rapacan
  • Siromus
  • Raparen
  • Rapasim
  • Sirova

Placebo Comparator: Placebo 1
Placebo once per week
Drug: Placebo
Placebo capsules




Primary Outcome Measures :
  1. Changes in visceral fat as measured by dual-energy x-ray absorptiometry (DXA) scan [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Visceral fat changes from baseline as determined by DXA scan.


Secondary Outcome Measures :
  1. bone density [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Changes in bone density from baseline as determined by DXA scan

  2. lean body mass [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Changes in lean body mass from baseline as determined by DXA scan

  3. adverse events [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Number of patients with adverse events using standard AE reporting (FDA regulations 21CFR314.80 and 1CFR213.32(s))

  4. complete blood count (CBC) [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    changes in CBC from baseline

  5. Change of blood electrolytes(serum potassium, sodium, chloride, and carbon dioxide in mmol/L)measured at baseline and after 6 and 12 months. [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Difference in the change of blood electrolytes(serum potassium, sodium, chloride, and carbon dioxide in mmol/L) compared with the baseline at 6 and 12 months between the intervention and control group is to be analyzed.

  6. Change of liver function as measured by serum globulin in g/dL, measured at baseline and after 6 and 12 months. [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Difference in the change of liver function as measured by serum globulin in g/dL compared with the baseline at 6 and 12 months between the intervention and control group is to be analyzed.

  7. Change of liver function as measured by serum bilirubin in mg/dL, measured at baseline and after 6 and 12 months. [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Difference in the change of liver function as measured by serum bilirubin in mg/dL compared with the baseline at 6 and 12 months between the intervention and control group is to be analyzed.

  8. Change of liver function as measured by serum alkaline phosphatase, AST, and ALT in IU/L, measured at baseline and after 6 and 12 months. [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Difference in the change of liver function as measured by serum alkaline phosphatase, AST, and ALT in IU/L compared with the baseline at 6 and 12 months between the intervention and control group is to be analyzed.

  9. Change of renal function as measured by serum albumin in g/dL, measured at baseline and after 6 and 12 months. [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Difference in the change of renal function as measured by serum albumin in g/dL compared with the baseline at 6 and 12 months between the intervention and control group is to be analyzed.

  10. Change of renal function as measured by serum creatinine and uric acid in mg/dL, measured at baseline and after 6 and 12 months. [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Difference in the change of renal function as measured by serum creatinine and uric acid in mg/dL compared with the baseline at 6 and 12 months between the intervention and control group is to be analyzed.

  11. Change in lipids (serum total cholesterol, triglycerides, HDL, and LDL cholesterol in mg/dL) measured at baseline and after 6 and 12 months. [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Difference in the change of lipids(serum total cholesterol, triglycerides, HDL and LDL cholesterol in mg/dL) compared with the baseline at 6 and 12 months between the intervention and control group is to be analyzed.

  12. Change in fasting serum glucose in mg/dL, measured at baseline and after 6 and 12 months. [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Difference in the change of fasting serum glucose in mg/dL compared with baseline at 6 and 12 months between the intervention and control group is to be analyzed.

  13. Change in insulin in uIU/mL, measured at baseline and after 6 and 12 months. [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Difference in the change of fasting serum insulin in uIU/mL compared with baseline at 6 and 12 months between the intervention and control group is to be analyzed.

  14. Change in fasting serum IGF-1 in ng/mL, measured at baseline and after 6 and 12 months. [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Difference in the change of fasting serum IGF-1 in ng/mL compared with baseline at 6 and 12 months between the intervention and control group is to be analyzed.

  15. Change in serum Hemoglobin A1c in % of total hemoglobin, measured at baseline and after 6 and 12 months. [ Time Frame: 6 month interim analysis of the data, 12 month safety profile will be established ]
    Difference in the change of serum Hemoglobin A1c in % of total hemoglobin compared with baseline at 6 and 12 months between the intervention and control group is to be analyzed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 50-85
  • Any sex
  • Any ethnicity
  • Interest in taking Rapamycin off-label
  • Willing to undergo tests
  • Relatively good health with only well-managed chronic diseases (hypertension, coronary artery disease, type II diabetes, etc.) clinically stable
  • Adequate cognitive function to be able to give informed consent
  • Technologically competent to complete web forms and perform video calls with the PI

Exclusion Criteria:

  • Anemia - Hg < 9.0 g/dl, Leukopenia - white blood cells (WBC) < 3,500/mm3 , Neutropenia - absolute neutrophil count < 2,000/mm3 , or Platelet count - platelet count < 125,000/mm3
  • Premenopausal females (due to menstruation-induced anemia, etc.)
  • Patients scheduled to undergo major surgery in the next 12 months
  • Patients undergoing or scheduled to undergo chemotherapy or any other treatment for malignancy
  • Patients scheduled for immunosuppressant therapy for transplant
  • Patients with impaired wound healing or history of a chronic open wound
  • Untreated dyslipidemia with LDL-c > 190 and family history of dyslipidemia, Total cholesterol > 350 mg/dl, or triglycerides > 880 mg/dl.
  • Impaired hepatic function, including elevated alkaline Phosphatase levels, aspartate aminotransferase (AST), alanine aminotransferase (ALT), Albumin, or T. Bili.
  • HIV/AIDS, chronic Lyme, Babesia, Ehrlichiosis, Anaplasmosis, or other chronic infections that require ongoing treatment or monitoring
  • Allergy to Rapamycin
  • Any form of clinically relevant primary or secondary immune dysfunction or deficiency (e.g. X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID))
  • Chronic oral corticosteroid or immunosuppressive medication use (e.g. Enbrel, Humira, methotrexate).
  • Fibromyalgia or Chronic Fatigue Syndrome/Myalgic Encephalomyelitis, Breast Implant Illness,
  • Congestive heart failure: self-assessed functional status of heart failure New York Heart Association (NYHA) classification III or IV
  • Impaired renal function, as defined as glomerular filtration rate (GFR) < 30
  • Poorly controlled diabetes, as defined as HbA1c > 7%
  • Type I Diabetes, or Insulin-dependent Type II diabetes
  • Substance abuse disorder either untreated or if treated within the last 5 years
  • PTSD, Bipolar disorder, Schizophrenia, or any other untreated or poorly controlled mental health or mood disorder, or history of hospitalization due to mental health condition
  • Those who have taken metformin, rapamycin, or rapalogs in the past 6 months

    • (volunteers who were on metformin for aging can participate, provided they agree to stop taking metformin before and during the trial)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04488601


Contacts
Layout table for location contacts
Contact: Sajad Zalzala, MD (313) 355-8657 doctor@agelessrx.com
Contact: James Watson, MD (805) 497-8411 jamespwatson@mac.com

Locations
Layout table for location information
United States, Illinois
AgelessRx Recruiting
Chicago, Illinois, United States, 60605
Contact: Sajad Zalzala, MD    313-355-8657    doctor@agelessrx.com   
Sponsors and Collaborators
AgelessRx
University of California, Los Angeles
Investigators
Layout table for investigator information
Principal Investigator: James Watson, MD University of California, Los Angeles
Study Director: Sajad Zalzala, MD AgelessRx
Layout table for additonal information
Responsible Party: AgelessRx
ClinicalTrials.gov Identifier: NCT04488601    
Other Study ID Numbers: ALRx001
First Posted: July 28, 2020    Key Record Dates
Last Update Posted: October 5, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: as soon as available
Access Criteria: Institutional review board (IRB) approval or at the discretion of PI/sponsor

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by AgelessRx:
rapamycin
aging
longevity
sirolimus
healthy aging
age-related conditions
Additional relevant MeSH terms:
Layout table for MeSH terms
Sirolimus
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs